Related Experiment Video

Updated: Jul 19, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

[Clinical stratification of cardiogenic shock]

Carlos Rodolfo Martínez Sánchez1, Jesús Octavio Martínez-Reding, Eulo Lupi Herrera

  • 1Instituto Nacional de Cardiología, Urgencias y Unidad Coronaria Juan Badiano # 1, Col. Sección XVI. marcar@cardiologia.org.mx

Archivos De Cardiologia De Mexico
|October 5, 2006
PubMed

Insights

Cardiogenic shock (CHC) following myocardial infarction has high mortality. Measuring cardiac power after reperfusion can identify high-risk patients, improving treatment strategies for better outcomes.

Area of Science:

  • Cardiology
  • Critical Care Medicine

Context:

  • Cardiogenic shock (CHC) complicating acute myocardial infarction presents heterogeneous manifestations and historically high mortality rates.
  • Institutional mortality for CHC was reduced from 98% to 53% with the implementation of reperfusion therapies.

Purpose:

  • To evaluate the utility of clinical stratification and hemodynamic assessment, specifically cardiac power, in managing patients with cardiogenic shock post-myocardial infarction.
  • To identify predictors of mortality in CHC patients undergoing reperfusion procedures.

Summary:

  • Clinical stratification involves assessing age, infarction location, heart rate, and systemic arterial pressure.
  • Hemodynamic evaluation using right heart catheterization quantifies myocardial work parameters, including "Cardiac Power" (cardiac output x mean arterial pressure).
  • In this experience, patients with CHC and cardiac power < 1.0 after reperfusion demonstrated significantly higher mortality.

Impact:

  • Opportune clinical and hemodynamic stratification can significantly improve treatment strategies for CHC.
  • Identifying patients with low cardiac power (< 1.0) post-reperfusion allows for targeted interventions to mitigate high mortality risks.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...